electroCore (ECOR) announced the completion of the merger with NeuroMetrix (NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach – particularly within the VA Hospital System – and is expected to meaningfully increase its addressable market for the treatment of chronic pain and wellness conditions.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECOR:
- electroCore’s Truvaga works with Apple Health app
- electroCore announces new data presented on nVNS
- electroCore extends VA contract for five years
- Electrocore’s Promising Growth and Strategic Positioning Earns Buy Rating from Analyst Vendetti
- ElectroCore’s Earnings Call: Robust Growth Amid Challenges